102 related articles for article (PubMed ID: 22555196)
1. RGD-modified endostatin fragments showed an antitumor effect through antiangiogenesis.
Pu CY; Xu HM; Hu JL; Zheng H; Huang XF; Zhang C; Yang YJ; Li YB
Anticancer Drugs; 2012 Sep; 23(8):788-802. PubMed ID: 22555196
[TBL] [Abstract][Full Text] [Related]
2. Effect of RGD-4C position is more important than disulfide bonds on antiangiogenic activity of RGD-4C modified endostatin derived synthetic polypeptide.
Yin R; Zheng H; Xi T; Xu HM
Bioconjug Chem; 2010 Jul; 21(7):1142-7. PubMed ID: 20515045
[TBL] [Abstract][Full Text] [Related]
3. An RGD-modified endostatin-derived synthetic peptide shows antitumor activity in vivo.
Xu HM; Yin R; Chen L; Siraj S; Huang X; Wang M; Fang H; Wang Y
Bioconjug Chem; 2008 Oct; 19(10):1980-6. PubMed ID: 18800818
[TBL] [Abstract][Full Text] [Related]
4. In vivo pharmacokinetics, immunogenicity and mechanism of PEGylated antitumor polypeptide.
Liu Z; Li W; Xu HM; Huang X; Pan L; Ren Y; Yang Y; Li Y; Pu C; Zhang C
Curr Pharm Des; 2012; 18(12):1655-62. PubMed ID: 22283767
[TBL] [Abstract][Full Text] [Related]
5. Addition of integrin binding sequence to a mutant human endostatin improves inhibition of tumor growth.
Yokoyama Y; Ramakrishnan S
Int J Cancer; 2004 Oct; 111(6):839-48. PubMed ID: 15300795
[TBL] [Abstract][Full Text] [Related]
6. Antiangiogenesis effects of endostatin in retinal neovascularization.
Bai YJ; Huang LZ; Zhou AY; Zhao M; Yu WZ; Li XX
J Ocul Pharmacol Ther; 2013 Sep; 29(7):619-26. PubMed ID: 23545016
[TBL] [Abstract][Full Text] [Related]
7. Generation of antitumor peptides by connection of matrix metalloproteinase-9 peptide inhibitor to an endostatin fragment.
Qiu Z; Hu J; Xu H; Wang W; Nie C; Wang X
Anticancer Drugs; 2013 Aug; 24(7):677-89. PubMed ID: 23652276
[TBL] [Abstract][Full Text] [Related]
8. The antiangiogenic and antitumor activities of the N-terminal fragment of endostatin augmented by Ile/Arg substitution: The overall structure implicated the biological activity.
Chamani R; Asghari SM; Alizadeh AM; Mansouri K; Doroudi T; Kolivand PH; Ghafouri H; Ehtesham S; Rabouti H; Mehrnejad F
Biochim Biophys Acta; 2016 Dec; 1864(12):1765-1774. PubMed ID: 27693049
[TBL] [Abstract][Full Text] [Related]
9. Regulation of tumor angiogenesis by fastatin, the fourth FAS1 domain of betaig-h3, via alphavbeta3 integrin.
Nam JO; Jeong HW; Lee BH; Park RW; Kim IS
Cancer Res; 2005 May; 65(10):4153-61. PubMed ID: 15899806
[TBL] [Abstract][Full Text] [Related]
10. Tat PTD-Endostatin-RGD: A novel protein with anti-angiogenesis effect in retina via eye drops.
Li Y; Li L; Li Z; Sheng J; Zhang X; Feng D; Zhang X; Yin F; Wang A; Wang F
Biochim Biophys Acta; 2016 Oct; 1860(10):2137-47. PubMed ID: 27233450
[TBL] [Abstract][Full Text] [Related]
11. Targeted delivery of RGD-modified liposomes encapsulating both combretastatin A-4 and doxorubicin for tumor therapy: in vitro and in vivo studies.
Zhang YF; Wang JC; Bian DY; Zhang X; Zhang Q
Eur J Pharm Biopharm; 2010 Mar; 74(3):467-73. PubMed ID: 20064608
[TBL] [Abstract][Full Text] [Related]
12. N-/C-terminal deleted mutant of human endostatin efficiently acts as an anti-angiogenic and anti-tumorigenic agent.
Cho H; Kim WJ; Lee YM; Kim YM; Kwon YG; Park YS; Choi EY; Kim KW
Oncol Rep; 2004 Jan; 11(1):191-5. PubMed ID: 14654925
[TBL] [Abstract][Full Text] [Related]
13. RGD-modified polymeric micelles as potential carriers for targeted delivery to integrin-overexpressing tumor vasculature and tumor cells.
Wang Y; Wang X; Zhang Y; Yang S; Wang J; Zhang X; Zhang Q
J Drug Target; 2009 Jul; 17(6):459-67. PubMed ID: 19527117
[TBL] [Abstract][Full Text] [Related]
14. Synthesis of Modified RGD-Based Peptides and Their in vitro Activity.
Hamdan F; Bigdeli Z; Asghari SM; Sadremomtaz A; Balalaie S
ChemMedChem; 2019 Jan; 14(2):282-288. PubMed ID: 30506622
[TBL] [Abstract][Full Text] [Related]
15. Anti-angiogenic effects of a mutant endostatin: a new prospect for treating retinal and choroidal neovascularization.
Bai Y; Zhao M; Zhang C; Li S; Qi Y; Wang B; Huang L; Li X
PLoS One; 2014; 9(11):e112448. PubMed ID: 25380141
[TBL] [Abstract][Full Text] [Related]
16. Delta-like ligand 4-targeted nanomedicine for antiangiogenic cancer therapy.
Liu YR; Guan YY; Luan X; Lu Q; Wang C; Liu HJ; Gao YG; Yang SC; Dong X; Chen HZ; Fang C
Biomaterials; 2015 Feb; 42():161-71. PubMed ID: 25542804
[TBL] [Abstract][Full Text] [Related]
17. Angiosuppressive and angiostimulatory effects exerted by synthetic partial sequences of endostatin.
Morbidelli L; Donnini S; Chillemi F; Giachetti A; Ziche M
Clin Cancer Res; 2003 Nov; 9(14):5358-69. PubMed ID: 14614021
[TBL] [Abstract][Full Text] [Related]
18. Control of angiogenesis by VEGF and endostatin-encapsulated protein microcrystals and inhibition of tumor angiogenesis.
Matsumoto G; Hirohata R; Hayashi K; Sugimoto Y; Kotani E; Shimabukuro J; Hirano T; Nakajima Y; Kawamata S; Mori H
Biomaterials; 2014 Jan; 35(4):1326-33. PubMed ID: 24210874
[TBL] [Abstract][Full Text] [Related]
19. Combination angiostatin and endostatin gene transfer induces synergistic antiangiogenic activity in vitro and antitumor efficacy in leukemia and solid tumors in mice.
Scappaticci FA; Smith R; Pathak A; Schloss D; Lum B; Cao Y; Johnson F; Engleman EG; Nolan GP
Mol Ther; 2001 Feb; 3(2):186-96. PubMed ID: 11237675
[TBL] [Abstract][Full Text] [Related]
20. Preparation of arginine-glycine-aspartic acid-modified biopolymeric nanoparticles containing epigalloccatechin-3-gallate for targeting vascular endothelial cells to inhibit corneal neovascularization.
Chang CY; Wang MC; Miyagawa T; Chen ZY; Lin FH; Chen KH; Liu GS; Tseng CL
Int J Nanomedicine; 2017; 12():279-294. PubMed ID: 28115846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
